TEST:

miRisk

Conclusion We have described a 16-miRNA, whole blood, qPCR signature that is prognostic in advanced stage NSCLC patients with high PD-L1 treated with IO but not ICT. This signature has utility as a complementary diagnostic for immunotherapy use in NSCLC and further supports the growing evidence that information beyond the TME can predict the efficacy of immunotherapies.

Furthermore, the miRisk score could identify a group of high-risk patients who may benefit from treatment with ICT as opposed to IO (hazard ratio = 0.35, 95% confidence interval: 0.15-0.82, p = 0.018). The miRisk score can distinguish a group of patients with PD-L1 high, stage IV NSCLC likely to benefit from adding chemotherapy to immunotherapy and may support treatment decisions as a blood-based complementary diagnostic.

"Hummingbird Diagnostics GmbH...announced a publication in the Journal of Thoracic Oncology Clinical and Research Reports that demonstrates their blood 5-microRNA signature (miRisk) to predict survival following immunotherapy in advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression...Hummingbird’s results demonstrate a significant association between overall survival (OS) and the miRisk score in IO treated patients and furthermore highlight its value as a predictive biomarker for type of treatment (IO or ICT)."